B
BORSA.BIOC Research Dossier
Markets Terminal
Glaxo Smith Kline
BIOCHealth Care & PharmaceuticalsISIN: EGS38171C012

Glaxo Smith Kline

جلاكسو سميثكلاين

291L.E
+0.66%+1.9 pts
Day Low: 289Day High: 299.85
EGX ClosedSource time: 2026-09-13 15:35
Previous Close
289.1
Open Price
289.1
Day High
299.85
Day Low
289
Turnover (EGP)
32.51M
Share Volume
110.77K
Trades Count
1,574
Market Cap
24.3B
Historical Price & Volume244 trading days

Period Return: +325.77%

2026-09-10

CLOSE289.1
VOLUME195.72K
TradingView Lightweight Charts™Daily Close & Volume points sourced from EGX

Financial Statement & Earnings Releases

Exact-ISIN matched results from EGX financial-statement and company-disclosure feeds.

EGX Financial Statements Source

Latest parsed result

Net profit · 01/01/2026 — 30/06/2026

consolidatedReviewed Comment : Taking into consideration minority rightsEGP

43.9M EGP

Comparative: 65.05M EGP

Profit -32.5% vs comparative period

Next reporting period

9M / Q3 2026 · period ends Sep 30, 2026

Company publication date: Not announced

Standard quarterly filing window: by Nov 14, 2026

Regulatory estimate only, based on the standard 45-day window and subject to FRA extensions. It is not a confirmed earnings date.

FRA filing rule
STRUCTURED EGX RESULT#293081consolidatedReviewed Comment : Taking into consideration minority rights

Glaxo Smith Kline (BIOC.CA) Reports 6 Months Consolidated Results

جلاكسو سميثكلاين (BIOC.CA) تعلن نتائج أعمالها المجمعة عن 6 أشهر

Period: 01/01/2026 — 30/06/2026Published: 2026-08-13 14:02ISIN: EGS38171C012
STRUCTURED EGX RESULT#293079standaloneReviewed

Glaxo Smith Kline (BIOC.CA) Reports 6 Months Standalone Results

جلاكسو سميثكلاين (BIOC.CA) تعلن نتائج أعمالها غير المجمعة عن 6 أشهر

Period: 01/01/2026 — 30/06/2026Published: 2026-08-13 14:00ISIN: EGS38171C012
STRUCTURED EGX RESULT#288332standaloneReviewed

Glaxo Smith Kline (BIOC.CA) Reports 3 Months Standalone Results

جلاكسو سميثكلاين (BIOC.CA) تعلن نتائج اعمالها غير المجمعة عن 3 أشهر

Period: 01/01/2026 — 31/03/2026Published: 2026-05-17 12:55ISIN: EGS38171C012
STRUCTURED EGX RESULT#288330consolidatedReviewed

Glaxo Smith Kline (BIOC.CA) Reports 3 Months Consolidated Results

جلاكسو سميثكلاين (BIOC.CA) تعلن نتائج اعمالها المجمعة عن 3 أشهر

Period: 01/01/2026 — 31/03/2026Published: 2026-05-17 12:53ISIN: EGS38171C012
Statement
STRUCTURED EGX RESULT#284833standaloneAudited

Glaxo Smith Kline (BIOC.CA) Reports Year Ended 31/12/2025 Standalone Results

جلاكسو سميثكلاين (BIOC.CA) تعلن نتائج اعمالها غير المجمعة عن السنة المالية المنتهية في 31/12/2025

Period: 01/01/2025 — 31/12/2025Published: 2026-03-12 11:59ISIN: EGS38171C012
Statement

Showing 5 of 12 structured statements

Official Corporate Disclosures

ISIN: EGS38171C012

Official regulatory filings, corporate announcements, dividend pay dates, and board resolutions.

EGX News Source
#293085Trading Notices2026-08-13 14:14

Resume of Trading on Glaxo Smith Kline (BIOC.CA)

إعادة التعامل على جلاكسو سميثكلاين (BIOC.CA)

Company Name : Glaxo Smith Kline ISIN Code : EGS38171C012 Reuters Code : BIOC.CA Content : Based on the decisions of the company's Board of Directors at its meeting held on 12/08/2026, EGX decided to resume trading on company's shares starting from 13/08/2026 trading session at 12:55 PM.

#293084General2026-08-13 14:14

Glaxo Smith Kline (BIOC.CA) - Board of Directors Decisions

جلاكسو سميثكلاين (BIOC.CA) - قرارات مجلس إدارة الشركة

Company Name : Glaxo Smith Kline ISIN Code : EGS38171C012 Reuters Code : BIOC.CA Content : Based on the decisions of the company's Board of Directors at its meeting held on 12/08/2026, EGX decided to resume trading in the company's shares starting from 13/08/2026 trading session at 12:55 PM. Board of Directors' Decisions in Arabic & English (937 KB) The BoD Report (3,369 KB) Release from the Company (306 KB)

Document 1Document 2Document 3
#293081Financial ResultsFinancial Report2026-08-13 14:02

Glaxo Smith Kline (BIOC.CA) Reports 6 Months Consolidated Results

جلاكسو سميثكلاين (BIOC.CA) تعلن نتائج أعمالها المجمعة عن 6 أشهر

Company Name : Glaxo Smith Kline ISIN Code : EGS38171C012 Currency : EGP F/S Consolidated Period : From 01/01/2026 To 30/06/2026 Net Profit : 43,898,726 F/S Consolidated Period : From 01/01/2025 To 30/06/2025 Net Comparative Profit : 65,052,473 Audit Status : Reviewed Comment : Taking into consideration minority rights Source : Glaxo Smith Kline

#293079Financial ResultsFinancial Report2026-08-13 14:00

Glaxo Smith Kline (BIOC.CA) Reports 6 Months Standalone Results

جلاكسو سميثكلاين (BIOC.CA) تعلن نتائج أعمالها غير المجمعة عن 6 أشهر

Company Name : Glaxo Smith Kline ISIN Code : EGS38171C012 Currency : EGP F/S Standalone Period : From 01/01/2026 To 30/06/2026 Net Profit : 67,466,432 F/S Standalone Period : From 01/01/2025 To 30/06/2025 Net Comparative Profit : 71,331,341 Audit Status : Reviewed Source : Glaxo Smith Kline

#293020Trading Notices2026-08-13 11:47

Suspension of Trading on Glaxo Smith Kline (BIOC.CA)

إيقاف التعامل على جلاكسو سميثكلاين (BIOC.CA)

Company Name : Glaxo Smith Kline ISIN Code : EGS38171C012 Reuters Code : BIOC.CA Content : Trading on company's shares will be suspended starting from today, 13/08/2026 trading session, in light of the notice issued by EGX to the company on 13/08/2026 regarding the decisions of the company's Board of Directors meeting held on 12/08/2026.

#292518General2026-08-05 16:08

Release from Glaxo Smith Kline (BIOC.CA) Regarding a Memorandum of Understanding

بيان من جلاكسو سميثكلاين (BIOC.CA) بخصوص مذكرة تفاهم

Company Name : Glaxo Smith Kline ISIN Code : EGS38171C012 Reuters Code : BIOC.CA Content : Release from the company regarding the memorandum of understanding with the Egyptian Drug Authority. Release from the Company (421 KB)

Document
#292379General2026-08-03 09:36

Release from Glaxo Smith Kline (BIOC.CA) Concerning a News Published on a Website

بيان من جلاكسو سميثكلاين (BIOC.CA) بخصوص أحد الأخبار المتداولة

Company Name : Glaxo Smith Kline ISIN Code : EGS38171C012 Reuters Code : BIOC.CA Content : With reference to what was published on a website under the title "GlaxoSmithKline and Relationship Therapeutics sign a $110 million agreement to develop AI-powered drug discovery", a release was issued by the company. Release from the Company (203 KB)

Document
#291659General2026-07-20 16:10

Release from Glaxo Smith Kline (BIOC.CA) Concerning the Stock Price

بيان من جلاكسو سميثكلاين (BIOC.CA) بخصوص سعر السهم

Company Name : Glaxo Smith Kline ISIN Code : EGS38171C012 Reuters Code : BIOC.CA Content : Release from the company stating that there is no material information that justify the stock movement. Release from the Company (201 KB)

Document

Showing 8 of 50 sourced records

Public EGX website snapshot. Production live redistribution requires licensing and permission from EGX / EGID.

EGX Website Source
Official Register

Company Facts & Ratios

Source

جلاكسو سميثكلاين

Latest earnings

Period ended Jun 30, 2026

EGX

43.9M EGP

Net profit-32.5% vs comparative periodconsolidated
Next reporting period

9M / Q3 2026 · ends Sep 30, 2026

Estimated FRA filing window: by Nov 14, 2026

ISIN Code
EGS38171C012
Sector
Health Care & Pharmaceuticals
Listing Date
1985-10-23
Listed Shares
83,514,200
Par Value
10 EGP
P/E Ratio
133.44
Dividend Yield
0.29%
Coupon Count
24
Latest Coupon
1 EGP
Coupon Pay Date
2026-01-14
Trading Schedule
Egyptian securities-Stocks
Regulatory Flags
IntradayTRUE
FACTUAL DATA COMPUTATION — NOT INVESTMENT ADVICE

Automated Market Liquidity & Price Note

  • Session DeltaThe snapshot is 1.9 L.E above the reported previous close. (Formula: current price − previous close).
  • Historical WindowAcross the available 703 trading days, the total close-to-close change is +760.42%.
  • Session LiquidityThe current snapshot reports 32.51M L.E turnover across 1,574 trades and 110.77K shares.